1Van Der Ven K, Skrabin S, Engels G, et al. HLA-G polymorphisms and allele frequencies in Caucasians. Hum Immunol, 1998,59:302-312.
2Schmidt CM, Ehlenfeldt RG, Athanasiou MC, et al. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. J Immunol, 1993,151:2633-2645.
3Moreau P, Paul P, Courand L, et al. HLA-G gene transcriptional regulation in trophoblasts and blood cells. Hum Immunol, 1997,52:41-46.
4Yang Y, Chu W, Geraghty DE, et al. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ. J Immunol, 1996,156:4224-4231.
5Storkus WJ, Alexander J, Payne JA, et al. Reversal of natural killing susceptibility in target cells expression transfected class I HLA genes. Proc Natl Acad Sci USA, 1989,86:2361-2370.
6Karlhofer FM, Ribuado RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49＋ IL-2-activated natural killer cells. Nature, 1992,358:66-70.
7Munz C, Holmes N, King A, et al. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J Exp Med, 1997,185:385-391.
8Perez-Villar JJ, Melero I, Navarro F, et al. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol, 1997,158:5736-5743.
9Borrego F, Ulbrecht M, Weiss EH, et al. Recognition of human histocompatibility leucocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med, 1998,187:813-818.
10Rouas-Freiss N, Marchal R,Kirszenbaum M, et al. The α1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA, 1997,94:5249-5254.
4Shimizu M, Fontana A, Takeda Y, et al. Induction of antitumor immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells J. Immunol, 1999, 162(12):7350 - 7357.
5Bennet MW, O'Connell J, Osulivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol, 1998, 160(11): 5669 - 5675.
6Max well M, Galanopoulos T, Neville-Golden J, et al. Effect of the expression of transforing growth fator-β2 in primary human glioblastomas immunosuppression and loss of immunesurveillance.J Neurosurg,1992,76(5) : 799 - 804.
7Fakhrai H, Dorigo O. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Nail Acad Sci USA, 1996, 93(6): 2909~2914.
8Leitlein J, Aulwurm S. Processing of Immunosuppressive Pro-TGF-β1, 2 by Human Glioma Cells Involves Cytoplasmic and Secreted Futin-Like Preteases. J Immunol, 2001, 166( 1 ) : 7238 - 7243.
9Colonna M, Samaridis J, Celia M, et al. Human meylomo onocytic cells express an inhiditory receptor for classical MHC class I'molecules. J Immunol, 1998, 160(6): 3096-3100.
10Lanier I,L. NK cell receptors. Anna Rev Immunol, 1998, 16(2): 359-393.
